DOCSLIB.ORG

A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells Claire Levrier1,2, Martin C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells Claire Levrier1,2, Martin C Published OnlineFirst October 19, 2016; DOI: 10.1158/1535-7163.MCT-16-0325 Small Molecule Therapeutics Molecular Cancer Therapeutics 6a-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells Claire Levrier1,2, Martin C. Sadowski1, Anja Rockstroh1, Brian Gabrielli3, Maria Kavallaris4,5, Melanie Lehman1,6, Rohan A. Davis2, and Colleen C. Nelson1 Abstract The lack of a cure for metastatic castrate-resistant prostate cer drug vinblastine, which included pathways involved in mito- cancer (mCRPC) highlights the urgent need for more efficient sis, microtubule spindle organization, and microtubule binding. drugs to fight this disease. Here, we report the mechanism of Like vinblastine, 6-AA inhibited microtubule polymerization action of the natural product 6a-acetoxyanopterine (6-AA) in in a cell-free system and reduced cellular microtubule polymer prostate cancer cells. At low nanomolar doses, this potent cyto- mass. Yet, microtubule alterations that are associated with resis- toxic alkaloid from the Australian endemic tree Anopterus tance to microtubule-destabilizing drugs like vinca alkaloids macleayanus induced a strong accumulation of LNCaP and PC- (vinblastine/vincristine) or 2-methoxyestradiol did not confer 3 (prostate cancer) cells as well as HeLa (cervical cancer) cells in resistance to 6-AA, suggesting a different mechanism of microtu- mitosis, severe mitotic spindle defects, and asymmetric cell divi- bule interaction. 6-AA is a first-in-class microtubule inhibitor that sions, ultimately leading to mitotic catastrophe accompanied by features the unique anopterine scaffold. This study provides a cell death through apoptosis. DNA microarray of 6-AA–treated strong rationale to further develop this novel structure class LNCaP cells combined with pathway analysis identified very of microtubule inhibitor for the treatment of malignant disease. similar transcriptional changes when compared with the antican- Mol Cancer Ther; 16(1); 3–15. Ó2016 AACR. Introduction lenged by known resistance pathways (2). The majority of anti- cancer drugs currently in use are natural products, natural product Prostate cancer is the second most diagnosed cancer in men in derivatives, or compounds developed on the basis of a natural developed countries and the fifth most common cause for cancer- product pharmacophore (3). Numerous organisms of various related deaths (1). Metastatic castrate-resistant prostate cancer biota independently developed a great diversity of natural pro- (mCRPC) remains an incurable disease despite the recent ducts throughout evolution as antipredatory defenses based on approvals of new and more efficacious therapeutics (2). This targeting microtubule dynamics (4). Microtubules are crucial for highlights the need for additional prostate cancer therapies, for cellular processes, such as cell division, mobility, intracellular example, drugs that inhibit proven targets, yet remain unchal- organelle transport, and endothelial cell biology (angiogenesis; ref. 5). Microtubules are highly dynamic protein structures, which continuously undergo growth through polymerization and 1Australian Prostate Cancer Research CentreÀQueensland, School of Biomed- shrinkage through depolymerization of a- and b-tubulin hetero- ical Sciences, Institute of Health and Biomedical Innovation, Queensland Uni- dimers (microtubule dynamics; ref. 6). In mitosis, microtubules versity of Technology, Princess Alexandra Hospital, Translational Research play a vital role in the assembly of the spindle apparatus and 2 Institute, Brisbane, Australia. Eskitis Institute for Drug Discovery, Griffith proper segregation of chromosomes to both daughter cells (6). University, Brisbane, Australia. 3Translational Research Institute, The University 4 This critical function has been successfully exploited for the of Queensland Diamantina Institute, Brisbane, Australia. Tumour Biology and fi Targeting Program, Children's Cancer Institute, Lowy Cancer Research Centre, development of anticancer drugs and is exempli ed by the semi- University of New South Wales Australia, New South Wales, Australia. 5ARC synthetic taxanes docetaxel and cabazitaxel, which are the FDA- Centre of Excellence in Convergent Bio-Nano Science and Technology and approved mainstay therapies of mCRPC (2). Vinca alkaloids (e.g., Australian Centre for NanoMedicine, University of New South Wales Australia, the natural products vinblastine, vincristine, and semisynthetic 6 New South Wales, Australia. Department of Urologic Sciences, Vancouver vinorelbine) are another class of microtubule inhibitors currently Prostate Centre, University of British Columbia, Vancouver, Canada. used as gold standards in chemotherapy for Hodgkin disease, Note: Supplementary data for this article are available at Molecular Cancer non-Hodgkin lymphoma, and breast cancer (6). At clinically Therapeutics Online (http://mct.aacrjournals.org/). relevant doses (low nanomolar), both drug classes kinetically Corresponding Author: Colleen C. Nelson, Queensland University of Technol- stabilize the microtubules, without changing microtubule poly- ogy, Translational Research Institute, Princess Alexandra Hospital, Brisbane, mer mass (7–9). This leads to mitotic arrest at the metaphase– Queensland 4102, Australia. Phone: 61-7-3176-7443; Fax: 61-7-3176-7440; anaphase transition, chromosome missegregation, genome insta- E-mail: [email protected] bility, and ultimately mitotic catastrophe and cell death (6). At doi: 10.1158/1535-7163.MCT-16-0325 higher concentrations (micromolar), taxanes stabilize microtu- Ó2016 American Association for Cancer Research. bules through binding to the taxane-binding site on b-tubulin www.aacrjournals.org 3 Downloaded from mct.aacrjournals.org on September 30, 2021. © 2017 American Association for Cancer Research. Published OnlineFirst October 19, 2016; DOI: 10.1158/1535-7163.MCT-16-0325 Levrier et al. (10). Vinca alkaloids bind to the vinca domain on b-tubulin and Assessment of cell viability and proliferation induce microtubule depolymerization (11). Another class of LNCaP (4,000 cells/well), HeLa (2,000 cells/well), and PC-3 microtubule destabilizers includes the natural products colchi- (3,000 cells/well) cells were seeded in 96-well plates and allowed cine, combretastatins, and 2-methoxyestradiol (2ME2), which all to attach for 24 hours. Cell viability as a function of metabolic interact with the colchicine domain located at the intradimer activity was measured by alamarBlue endpoint assay (Thermo interface between a/b-tubulin heterodimers, leading to microtu- Fisher Scientific) after 72 hours of treatment (20). Nonadherent bule depolymerization (12). Since the development of vinblas- T-ALL cell lines (20,000 cells/well) were simultaneously seeded in tine and paclitaxel, other natural product–derived microtubule 96-well plates and treated with the indicated compounds for 72 inhibitors have reached the market. Sagopilone (epothilone ana- hours. Cell proliferation as a function of cell confluence was logue, stabilizer) has shown very promising results in a phase II evaluated using live-cell imaging (IncuCyte, Essen BioScience) clinical trial in mCRPC (13). The FDA-approved microtubule- as described before (20). depolymerizing agent eribulin has shown activity in a phase II clinical trial (14). Despite their initial therapeutic success, resis- Cell-cycle analysis by flow cytometry tance to these agents develops. Known resistance mechanisms LNCaP cells were plated in 6-well plates (150,000 cells/well), induced by microtubule inhibitors include drug efflux through allowed to attach for 24 hours, and treated with the indicated increased expression of multidrug resistance transporters, tubulin compounds for 24 hours. Cell-cycle experiments were conducted isoform expression, and mutations (6). We have previously as described previously (21). Samples were analyzed on a FACS- reported the identification and cytotoxicity analysis of eight Canto (BD Biosciences). DNA histograms were analyzed using C diterpenoid alkaloids that feature the unique anopterine 20 ModFit LT software (Verity Software House). scaffold from the Australian endemic rainforest plant Anopterus macleayanus (15). The anopterine analogues induced cell death in a panel of prostate cancer cell lines at nanomolar concentrations Wound closure assay (15). Here, we present the mechanism-of-action studies of the PC-3 cells (30,000 cells/well) were seeded in 96-well Image- most potent anopterine analogue, 6a-acetoxyanopterine (6-AA) Lock plates (Essen BioScience) and allowed to attach for 24 hours. and provide evidence that the anopterine scaffold represents a Wounds were generated with a 96-well mechanical Woundmaker novel structure class of microtubule inhibitors with a mechanism (Essen BioScience); cells were treated with the indicated com- of interaction that is distinct to taxanes, vinca alkaloids, and pounds for 16 hours. Wound closure was measured using a live- 2-methoxyestradiol. This is the first time that such activity has cell imaging system (IncuCyte) according to the manufacturer's been described for this structure class. instructions (Essen BioScience). Materials and Methods Microarray gene expression profiling LNCaP cells were seeded and allowed to attach for 24 hours in a Reagents Vinblastine, colchicine, nocodazole, verapamil, 2-methoxyes- 6-well plate (150,000 cells/well) then treated with 6-AA (10 nmol/L) or vinblastine (3.25 nmol/L) for 24 hours before RNA tradiol (all Sigma-Aldrich),
Load more

Recommended publications
  • Modifications on the Basic Skeletons of Vinblastine and Vincristine
    Molecules 2012, 17, 5893-5914; doi:10.3390/molecules17055893 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Modifications on the Basic Skeletons of Vinblastine and Vincristine Péter Keglevich, László Hazai, György Kalaus and Csaba Szántay * Department of Organic Chemistry and Technology, University of Technology and Economics, H-1111 Budapest, Szt. Gellért tér 4, Hungary * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel: +36-1-463-1195; Fax: +36-1-463-3297. Received: 30 March 2012; in revised form: 9 May 2012 / Accepted: 10 May 2012 / Published: 18 May 2012 Abstract: The synthetic investigation of biologically active natural compounds serves two main purposes: (i) the total synthesis of alkaloids and their analogues; (ii) modification of the structures for producing more selective, more effective, or less toxic derivatives. In the chemistry of dimeric Vinca alkaloids enormous efforts have been directed towards synthesizing new derivatives of the antitumor agents vinblastine and vincristine so as to obtain novel compounds with improved therapeutic properties. Keywords: antitumor therapy; vinblastine; vincristine; derivatives 1. Introduction Vinblastine (1) and vincristine (2) are dimeric alkaloids (Figure 1) isolated from the Madagaskar periwinkle plant (Catharantus roseus), exhibit significant cytotoxic activity and are used in the antitumor therapy as antineoplastic agents. In the course of cell proliferation they act as inhibitors during the metaphase of the cell cycle and by binding to the microtubules inhibit the development of the mitotic spindle. In tumor cells these agents inhibit the DNA repair and the RNA synthesis mechanisms, blocking the DNA-dependent RNA polymerase. Molecules 2012, 17 5894 Figure 1.
    [Show full text]
  • Human Cytogenetics Prenatal Diagnostics
    Cytogenetics Human Cytogenetics Prenatal Diagnostics Optimized Medium for Culture and Genetic Analysis of Human Amniotic Fluid Cells BIOAMF-1 and Chorionic Villi ( CV ) Samples Basal Medium and Supplement Chromosome Karyotyping was first developed in the BIOAMF-1 is designed for the primary culture of field of Cytogenetics. human amniotic fluid cells and chorionic villi (CV) The basic principle of the method is the preparation samples in both open (5% CO2) and closed systems. of chromosomes for microscopic observation by The medium allows rapid growth of amniocytes or arresting cell mitosis at metaphase with colchicine and treating the cells with a hypotonic solution. This chorionic villi for use in karyotyping. is followed by regular or fluorescent staining of the No supplementation with serum or serum- chromosomes, which are then tested with the aid of a substitutes is necessary. microscope and computer programs to arrange and The medium consists of two components: basal identify the chromosomes for the presence of genetic medium and frozen supplements. abnormalities. In principle, this method enables the identification Instructions for Use of any abnormality - excess chromosomes or For the preparation of 500ml complete medium, use chromosome deficiency, broken chromosomes, 01-190-1A with 01-192-1E. or excess genetic material (as a result of a For the preparation of 100ml complete medium, use recombination process). 01-190-1B with 01-192-1D. Clinical cytogenetics laboratories use this method Thaw the BIOAMF-1 Supplement by swirling in a with amniotic fluid, chorionic villi, blood cells, skin cells, and so on, which can be cell cultured to obtain 37ºC water bath, and transfer the contents to the mitotic cells.
    [Show full text]
  • Mandatory Standard for Vinca Alkaloids
    Mandatory Standard for vinca alkaloids 1. Introduction Vinca alkaloids are a class of chemotherapeutic agents which includes vinblastine, vincristine, vinflunine and vinorelbine. Health Service Providers are required to have local guidelines in place which adhere to the minimum safety requirements outlined in this Standard. This Standard is based on a national alert on vinca alkaloids developed by the Australian Council for Safety and Quality in Health Care. The Australian Commission for Safety and Quality in Health Care published an updated alert in February 2019.1 2. Vinca Alkaloids Standard While any medication administered via the incorrect route can result in harm, the inadvertent intrathecal administration of vinca alkaloids has resulted in death or permanent disability and remains a potential risk.2 Vinca alkaloids can be fatal if given by the intrathecal route and must therefore ONLY be administered intravenously. Specific requirements for hospitals and health services are outlined below. 2.1 Prescribing requirements • In accordance with the Clinical Oncological Society of Australia guidelines, vinca alkaloids must only be prescribed by medical practitioners with appropriate skills, training and qualifications in the management of cancer. • Dosing of vinca alkaloids must be calculated by a medical practitioner skilled in this task. 2.2 Preparation and dispensing • All vinca alkaloids must be prepared and supplied in a minibag of compatible solution, never in a syringe. For adult dosing the minibag must contain a total volume of 50mL or more. • Vinca alkaloids must only be prepared and dispensed by appropriately trained staff that have been assessed as competent to prepare and dispense chemotherapy. The total milligram dose of vinca alkaloid to be added to the minibag must be verified by a chemotherapy competent pharmacist before it is dispensed in the Pharmacy Compounding Unit.
    [Show full text]
  • Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
    cancers Review Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer Lukas Gorecki 1 , Martin Andrs 1,2 and Jan Korabecny 1,* 1 Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic; [email protected] (L.G.); [email protected] (M.A.) 2 Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic * Correspondence: [email protected]; Tel.: +420-495-833-447 Simple Summary: Selective killing of cancer cells is privileged mainstream in cancer treatment and targeted therapy represents the new tool with a potential to pursue this aim. It can also aid to overcome resistance of conventional chemo- or radio-therapy. Common mutations of cancer cells (defective G1 control) favor inhibiting intra-S and G2/M-checkpoints, which are regulated by ATR–CHK1–WEE1 pathway. The ATR–CHK1–WEE1 axis has produced several clinical candidates currently undergoing clinical trials in phase II. Clinical results from randomized trials by ATR and WEE1 inhibitors warrant ongoing clinical trials in phase III. Abstract: Selective killing of cancer cells while sparing healthy ones is the principle of the perfect cancer treatment and the primary aim of many oncologists, molecular biologists, and medicinal chemists. To achieve this goal, it is crucial to understand the molecular mechanisms that distinguish cancer cells from healthy ones. Accordingly, several clinical candidates that use particular mutations in cell-cycle progressions have been developed to kill cancer cells. As the majority of cancer cells have defects in G1 control, targeting the subsequent intra-S or G2/M checkpoints has also been extensively Citation: Gorecki, L.; Andrs, M.; pursued.
    [Show full text]
  • The Phytochemical Analysis of Vinca L. Species Leaf Extracts Is Correlated with the Antioxidant, Antibacterial, and Antitumor Effects
    molecules Article The Phytochemical Analysis of Vinca L. Species Leaf Extracts Is Correlated with the Antioxidant, Antibacterial, and Antitumor Effects 1,2, 3 3 1 1 Alexandra Ciorît, ă * , Cezara Zăgrean-Tuza , Augustin C. Mot, , Rahela Carpa and Marcel Pârvu 1 Faculty of Biology and Geology, Babes, -Bolyai University, 44 Republicii St., 400015 Cluj-Napoca, Romania; [email protected] (R.C.); [email protected] (M.P.) 2 National Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donath St., 400293 Cluj-Napoca, Romania 3 Faculty of Chemistry and Chemical Engineering, Babes, -Bolyai University, 11 Arany János St., 400028 Cluj-Napoca, Romania; [email protected] (C.Z.-T.); [email protected] (A.C.M.) * Correspondence: [email protected]; Tel.: +40-264-584-037 Abstract: The phytochemical analysis of Vinca minor, V. herbacea, V. major, and V. major var. variegata leaf extracts showed species-dependent antioxidant, antibacterial, and cytotoxic effects correlated with the identified phytoconstituents. Vincamine was present in V. minor, V. major, and V. major var. variegata, while V. minor had the richest alkaloid content, followed by V. herbacea. V. major var. variegata was richest in flavonoids and the highest total phenolic content was found in V. herbacea which also had elevated levels of rutin. Consequently, V. herbacea had the highest antioxidant activity V. major variegata V. major V. minor followed by var. Whereas, the lowest one was of . The extract showed the most efficient inhibitory effect against both Staphylococcus aureus and E. coli. On the other hand, V. herbacea had a good anti-bacterial potential only against S.
    [Show full text]
  • (10) Patent No.: US 9562099 B2
    USO09562099B2 (12) United States Patent (10) Patent No.: US 9,562,099 B2 Leong et al. (45) Date of Patent: Feb. 7, 2017 (54) ANTI-B7-H4 ANTIBODIES AND 4,260,608 A 4, 1981 Miyashita et al. MMUNOCONUGATES 4,265,814 A 5/1981 Hashimoto et al. 4.294,757 A 10, 1981 Asai (71) Applicant: Genentech, Inc., South San Francisco, 4,307,016 A 12/1981 Asai et al. CA (US) 4,308,268 A 12/1981 Miyashita et al. 4,308,269 A 12/1981 Miyashita et al. (72) Inventors: Steven R. Leong, Berkeley, CA (US); 4,309.428 A 1/1982 Miyashita et al. Andrew Polson, San Francisco, CA 4,313,946 A 2f1982 Powell et al. (US); s Paul Polakis,s Mill Valley,y, CA 4,317,8214,315,929 A 3/19822, 1982 MiyashitaFreedman et al. (US); Yan Wu, Foster City, CA (US); 4.322,348 A 3/1982 Asai et al. Wei-Ching Liang, Foster City, CA 4.331,598. A 5/1982 Hasegawa et al. (US); Ron Firestein, Burlingame, CA 4,361,650 A 1 1/1982 Asai et al. (US) 4,362,663 A 12/1982 Kida et al. 4,364,866 A 12/1982 Asai et al. (73) Assignee: Genentech, Inc., South San Francisco, 4,371.533. A 2, 1983 Akimoto et al. CA (US) 4.424,219 A 1/1984 Hashimoto et al. 4.450,254 A 5/1984 Isley et al. (*) Notice: Subject to any disclaimer, the term of this 4,676.980 A 6/1987 Segal et al.
    [Show full text]
  • Actin Gesting That Cytoskeletal Laments May Be Exploited to Supplement Chemotherapeutic Approaches Currently Used Microfilaments in the Clinical Setting
    Biochimica et Biophysica Acta 1846 (2014) 599–616 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbacan Review Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach Matthew Trendowski ⁎ Department of Biology, Syracuse University, 107 College Place, Syracuse, NY 13244, USA article info abstract Article history: Although cytoskeletal-directed agents have been a mainstay in chemotherapeutic protocols due to their ability to Received 2 August 2014 readily interfere with the rapid mitotic progression of neoplastic cells, they are all microtubule-based drugs, and Received in revised form 19 September 2014 there has yet to be any microfilament- or intermediate filament-directed agents approved for clinical use. There Accepted 21 September 2014 are many inherent differences between the cytoskeletal networks of malignant and normal cells, providing an Available online 5 October 2014 ideal target to attain preferential damage. Further, numerous microfilament-directed agents, and an intermediate fi fi Keywords: lament-directed agent of particular interest (withaferin A) have demonstrated in vitro and in vivo ef cacy, sug- fi Actin gesting that cytoskeletal laments may be exploited to supplement chemotherapeutic approaches currently used Microfilaments in the clinical setting. Therefore, this review is intended to expose academics and clinicians to the tremendous Intermediate filaments variety of cytoskeletal filament-directed agents that are currently available for further chemotherapeutic evalu- Drug synergy ation. The mechanisms by which microfilament directed- and intermediate filament-directed agents damage Chemotherapy malignant cells are discussed in detail in order to establish how the drugs can be used in combination with each other, or with currently approved chemotherapeutic agents to generate a substantial synergistic attack, potentially establishing a new paradigm of chemotherapeutic agents.
    [Show full text]
  • Elevated MARCKS Phosphorylation Contributes to Unresponsiveness of Breast Cancer to Paclitaxel Treatment
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 17 Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment Ching-Hsien Chen1, Chun-Ting Cheng2,3, Yuan Yuan4, Jing Zhai5, Muhammad Arif1, Lon Wolf R. Fong1, Reen Wu1 and David K. Ann2,3 1 Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine and Center for Comparative Respiratory Biology and Medicine, University of California Davis, California, USA 2 Department of Molecular Pharmacology, Beckman Research Institute, City of Hope, Duarte, California, USA 3 Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute, City of Hope, Duarte, California, USA 4 Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA 5 Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, California, USA Correspondence to: David K. Ann, email: [email protected] Correspondence to: Reen Wu, email: [email protected] Keywords: phospho-MARCKS, MANS peptide, paclitaxel, mitotic inhibitor, breast cancer Received: December 23, 2014 Accepted: March 26, 2015 Published: April 14, 2015 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Accumulating evidence has suggested that myristoylated alanine-rich C-kinase substrate (MARCKS) is critical for regulating multiple pathophysiological processes. However, the molecular mechanism underlying increased phosphorylation of MARCKS at Ser159/163 (phospho-MARCKS) and its functional consequence in neoplastic disease remain to be established. Herein, we investigated how phospho-MARCKS is regulated in breast carcinoma, and its role in the context of chemotherapy.
    [Show full text]
  • Inhibition of Polo-Like Kinase 4 Induces Mitotic Defects and DNA Damage in Diffuse Large B-Cell Lymphoma
    www.nature.com/cddis ARTICLE OPEN Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma 1 1 1 1 1 1 1 1,2,3,4,5,6 ✉ Yi Zhao , Juan Yang✉ , Jiarui Liu , Yiqing Cai , Yang Han , Shunfeng Hu , Shuai Ren , Xiangxiang Zhou and Xin Wang 1,2,3,4,5,6 © The Author(s) 2021 Polo-like kinase 4 (PLK4), a key regulator of centriole biogenesis, has recently been shown to play key roles in tumorigenesis. Blocking PLK4 expression by interference or targeted drugs exhibits attractive potential in improving the efficacy of chemotherapy. Nevertheless, the role of PLK4 in diffuse large B-cell lymphoma (DLBCL) is still undefined. In this study, we discover that PLK4 is a potential target for the treatment of DLBCL, and demonstrate the efficacy of a PLK4 inhibitor when used in combination with doxorubicin. Pharmaceutical inhibition of PLK4 with CFI-400945 inhibited DLBCL cell proliferation and induced apoptotic cell death. The anti-tumor effects were accompanied by mitotic defects, including polyploidy and cytokinesis failure. Activation of p53 and Hippo/YAP tumor suppressor signaling pathway was identified as the potential mechanisms driving CFI-400945 activity. Moreover, CFI-400945 treatment resulted in activation of DNA damage response. Combining CFI-400945 with doxorubicin markedly delayed tumor progression in DLBCL xenografts. Finally, PLK4 was increased in primary DLBCL tissues and cell lines. High levels of PLK4 expression were associated with poor survival in the patients receiving CHOP-based treatment, implicating PLK4 as a predictive biomarker of DLBCL chemosensitivity. These results provide the therapeutic potential of CFI-400945 both as monotherapy or in combination with doxorubicin for the treatment of DLBCL.
    [Show full text]
  • Review Article Vincristine-Induced Peripheral Neuropathy in Pediatric Cancer Patients
    Am J Cancer Res 2016;6(11):2416-2430 www.ajcr.us /ISSN:2156-6976/ajcr0042915 Review Article Vincristine-induced peripheral neuropathy in pediatric cancer patients Erika Mora1, Ellen M Lavoie Smith2, Clare Donohoe2, Daniel L Hertz3 1Department of Pediatrics, Division of Pediatric Heme/Onc, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Health Behavior and Biological Sciences, University of Michigan School of Nursing, Ann Arbor, MI, USA; 3Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109-1065, United States Received October 26, 2016; Accepted October 28, 2016; Epub November 1, 2016; Published November 15, 2016 Abstract: Vincristine is a chemotherapeutic agent that is a component of many combination regimens for a vari- ety of malignancies, including several common pediatric tumors. Vincristine treatment is limited by a progressive sensorimotor peripheral neuropathy. Vincristine-induced peripheral neuropathy (VIPN) is particularly challenging to detect and monitor in pediatric patients, in whom the side effect can diminish long term quality of life. This review summarizes the current state of knowledge regarding VIPN, focusing on its description, assessment, prediction, prevention, and treatment. Significant progress has been made in our knowledge about VIPN incidence and progres- sion, and tools have been developed that enable clinicians to reliably measure VIPN in pediatric patients. Despite these successes, little progress has been made in identifying clinically useful predictors of VIPN or in developing ef- fective approaches for VIPN prevention or treatment in either pediatric or adult patients. Further research is needed to predict, prevent, and treat VIPN to maximize therapeutic benefit and avoid unnecessary toxicity from vincristine treatment.
    [Show full text]
  • Metabolomics Analysis Reveals Both Plant Variety and Choice of Hormone Treatment Modulate Vinca Alkaloid Production in Catharanthus Roseus
    Metabolomics analysis reveals both plant variety and choice of hormone treatment modulate vinca alkaloid production in Catharanthus roseus. Valerie N. Fraser†‡, Benjamin Philmus§⊥*, Molly Megraw‡⊥*. †Molecular and Cellular Biology Program, Oregon State University, Corvallis, Oregon 97331, United States. ‡Department of Botany and Plant Pathology, Oregon State University, Corvallis, Oregon 97331, United States. §Department of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331, United States. ⊥Center for Genomics and Biocomputing, Oregon State University, Corvallis, Oregon 97331, United States. 1 ABSTRACT. The medicinal plant Catharanthus roseus produces numerous secondary metabolites of interest for the treatment of many diseases—most notably for the terpene indole alkaloid (TIA) vinblastine, which is used in the treatment of leukemia and Hodgkin’s lymphoma. Historically, methyl jasmonate (MeJA) has been used to induce TIA production, but in the past, this has only been investigated in either whole seedlings, cell culture, or hairy root culture. In this work, we investigate the induction capabilities of MeJA and ethylene, a different phytohormone, in both the shoots and roots of two varieties of C. roseus. Using LCMS and RT-qPCR, we demonstrate the importance of variety selection, as we observe markedly different induction patterns of important TIA precursor compounds. Additionally, both phytohormone choice and concentration have significant effects on TIA biosynthesis. Finally, our study suggests that several early- induction pathway steps as well as pathway-specific genes are likely to be transcriptionally regulated. Our findings highlight the need for a complete set of ’omics resources in commonly used C. roseus varieties. 2 Many plant-derived secondary metabolites have chemical properties that give them therapeutic value for the treatment of cancers, hypertension, and other illnesses1.
    [Show full text]
  • Human Karyotyping Open Small Res
    HUMAN CYTOGENETICS www.bioind.com Biological Industries With over 35 years of expertise in cell culture media development and manufacturing, Biological Industries’ (BI) products including BIO-AMF™, BIO-HEMATO™, and BIO-PB™ brands—are used in cytogenetic laboratories all around the world. Our cytogenetic product line gives you the option of selecting high quality tools that can help you make critical decisions in the lab. When your cytogenetics analysis is supported by the BI-team and BI media and supplements, you can be confident in the conclusions you reach. Today, our product and services portfolio benefits both life science and medical customers. Whether it is in developing culture media for cell therapy, media to assist IVF procedures, or supplying media and reagents for classical cell culture, we are committed to providing our customers with a Culture of Excellence. We do this through our advanced GMP manufacturing and quality control systems, superior regulatory expertise, in-depth market knowledge, and extensive technical customer support, training, and R&D capabilities. BOOST PERFORMANCE INCREASE CONSISTENCY Performance Quality Control Support • Consistent lot-to-lot performance • Manufactured in compliance with • Regional technical support • Optimized products for the analysis the FDA’s quality system regulation • Documentation and traceability of amniotic fluid, chorionic villus, (cGMP) and the current requirements of documentation including Certificate peripheral blood, bone marrow, ISO 9001 and ISO 13485 of Analysis, and Certificates
    [Show full text]